Answers are grounded in this paper and cite their sources.
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial-derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined.
No takes yet. Share an insight, caveat, or question.
Sherer et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: